Announcements
28 May 2025
Meet Us at the 47th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 14–18 July 2025, Copenhagen, Denmark
7 July 2025
Meet Us at the European Academy of Dermatology & Venereology (EADV) 2025, 17–20 September 2025, Paris, France
7 July 2025
Journal of Clinical Medicine | Highly Cited Papers and Hot Topic Special Issues on Liver Diseases
Chronic liver disease is a major global health challenge and has long posed a serious threat to the quality of human life. We sincerely recommend the highly cited papers on liver diseases selected in the Journal of Clinical Medicine (JCM, ISSN: 2077-0383) in the past two years. Each of them is the result of the hard work and wisdom of elite scientific researchers. These selected papers cover multiple dimensions, such as liver transplantation technology innovation, liver fibrosis, and nonalcoholic fatty liver disease. Medical practitioners and enthusiasts are welcome to read for free. At the same time, the channel for soliciting papers on liver diseases in JCM has been opened. We recommend four hot Special Issues for you, and we look forward to your cutting-edge research and innovative results. For more research on liver diseases, please check: https://www.mdpi.com/search?advanced=(@(title)liver.
1. “Introducing Machine Perfusion into Routine Clinical Practice for Liver Transplantation in the United States: The Moment Has Finally Come”
Kristopher P. Croome
J. Clin. Med. 2023, 12(3), 909; https://doi.org/10.3390/jcm12030909
Full text available online: https://www.mdpi.com/2077-0383/12/3/909
2. “Metabolic Disorders in Liver Transplant Recipients: The State of the Art”
by Filippo Gabrielli, Lucia Golfieri, Fabio Nascimbeni, Pietro Andreone and Stefano Gitto
J. Clin. Med. 2024, 13(4), 1014; https://doi.org/10.3390/jcm13041014
Full text available online: https://www.mdpi.com/2077-0383/13/4/1014
3. “The Interplay between Liver Sinusoidal Endothelial Cells, Platelets, and Neutrophil Extracellular Traps in the Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease”
by Iulia Minciuna, Madalina Gabriela Taru, Bogdan Procopet and Horia Stefanescu
J. Clin. Med. 2024, 13(5), 1406; https://doi.org/10.3390/jcm13051406
Full text available online: https://www.mdpi.com/2077-0383/13/5/1406
4. “Efficacy and Safety of a Probiotic Containing Saccharomyces boulardii CNCM I-745 in the Treatment of Small Intestinal Bacterial Overgrowth in Decompensated Cirrhosis: Randomized, Placebo-Controlled Study”
by Irina Efremova, Roman Maslennikov, Maria Zharkova, Elena Poluektova, Nona Benuni, Aleksandr Kotusov, Tatyana Demina, Aleksandra Ivleva, Farida Adzhieva, Taisiya Krylova et al.
J. Clin. Med. 2024, 13(3), 919; https://doi.org/10.3390/jcm13030919
Full text available online: https://www.mdpi.com/2077-0383/13/3/919
5. “Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients”
by Chinmay Bera, Nashla Hamdan-Perez and Keyur Patel
J. Clin. Med. 2024, 13(4), 1046; https://doi.org/10.3390/jcm13041046
Full text available online: https://www.mdpi.com/2077-0383/13/4/1046
6. “Hepatitis B Virus Reactivation with Immunosuppression: A Hidden Threat?”
by Sama Anvari and Keith Tsoi
J. Clin. Med. 2024, 13(2), 393; https://doi.org/10.3390/jcm13020393
Full text available online: https://www.mdpi.com/2077-0383/13/2/393
7. “Steatotic Liver Disease and Sepsis Outcomes—A Prospective Cohort Study (SepsisFAT)”
by Juraj Krznaric, Neven Papic, Nina Vrsaljko, Branimir Gjurasin, Marko Kutlesa and Adriana Vince
J. Clin. Med. 2024, 13(3), 798; https://doi.org/10.3390/jcm13030798
Full text available online: https://www.mdpi.com/2077-0383/13/3/798
8. “Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD)”
by Damian Dyńka, Łukasz Rodzeń, Mateusz Rodzeń, Dorota Łojko, Sebastian Kraszewski, Ali Ibrahim, Maria Hussey, Adam Deptuła, Żaneta Grzywacz, Alexandre Ternianov et al.
J. Clin. Med. 2024, 13(16), 4857; https://doi.org/10.3390/jcm13164857
Full text available online: https://www.mdpi.com/2077-0383/13/16/4857
9. “Hepatitis C Virus (HCV) Infection: Pathogenesis, Oral Manifestations, and the Role of Direct-Acting Antiviral Therapy: A Narrative Review”
by Dario Di Stasio, Agostino Guida, Antonio Romano, Massimo Petruzzi, Aldo Marrone, Fausto Fiori and Alberta Lucchese
J. Clin. Med. 2024, 13(14), 4012; https://doi.org/10.3390/jcm13144012
Full text available online: https://www.mdpi.com/2077-0383/13/14/4012
10. “The Prognostic Value of a Liver Function Test Using Indocyanine Green (ICG) Clearance in Patients with Multiple Organ Dysfunction Syndrome (MODS)”
by Franz Haertel, Sebastian Nuding, Diana Reisberg, Martin Peters, Karl Werdan, P. Christian Schulze and Henning Ebelt
J. Clin. Med. 2024, 13(4), 1039; https://doi.org/10.3390/jcm13041039
Full text available online: https://www.mdpi.com/2077-0383/13/4/1039
|
Special Issues |
|
|
“Clinical Advances in Metabolic Dysfunction-Associated Steatotic Liver Disease” |
“Advances in Hepatitis: Prevention, Treatment, and Global Health Impact” |
 |
 |
|
“Clinical Updates and Personalized Medicine in Hepatocellular Carcinoma and Liver Transplantation” |
“Current and Emerging Treatment Options in Chronic Liver Diseases” |
 |
 |
4 July 2025
MDPI’s Newly Launched Journals in June 2025
Six new journals covering a range of subjects launched their inaugural issues in June 2025. We are excited to be able to share with you the newest research rooted in the value of open access. We are pleased to present the latest research and to make it accessible to all.
We extend our sincere thanks to all the Editorial Board Members for their commitment and expertise. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.
Please feel free to browse and discover more about the new journals below.
| Journal | Founding Editor-in-Chief | Journal Topics (Selected) |
 |
Prof. Dr. Chang-Pu Sun, China Academy of Engineering Physics, Beijing, China; Computational Science Research Center, China Editorial | View inaugural issue |
quantum information and phenomena; condensed matter physics and statistical physics; atomic, molecular, and optical physics; computational physics and mathematical methods View journal scope | Submit an article |
 |
Prof. Dr. Hualiang Lin, Sun Yat-sen University, China; Prof. Dr. Jose L. Domingo, Universitat Rovira i Virgili, Spain Editorial | View inaugural issue |
green and organic food; green infrastructures; green exercise; environmental impact of the healthcare sector; effects of climate change on human health | View journal scope | Submit an article |
 |
Prof. Dr. Francesco Veglio, University of L’Aquila, Italy Editorial | View inaugural issue |
ultra-pure substances; water purification; air purification; gas purification; inorganic chemical purification; purification technologies View journal scope | Submit an article |
 |
Prof. Dr. Junxing Zheng, Huazhong University of Science and Technology, China Editorial | View inaugural issue |
computer-aided design and engineering; artificial intelligence and machine learning; building information modeling (BIM) and digital twins; robotics and automation in construction; smart sensors and Internet of Things (IoT); intelligent control systems and facilities management View journal scope | Submit an article |
 |
Prof. Dr. Assunta Di Vaio, University of Naples Parthenope, Italy Editorial | View inaugural issue |
sustainability, managerial, and biodiversity accounting; carbon management accounting; corporate social responsibility; artificial intelligence and disclosure View journal scope | Submit an article |
 |
Prof. Dr. Changjun Liu, Sichuan University, China Editorial | View inaugural issue |
bioeffects of electromagnetic waves; electromagnetic science and engineering; microwave, millimeter-wave, and terahertz technologies; metamaterials and metasurfaces; communication, sensing, and networks; energy, power, and sustainable applications; quantum and emerging technologies; artificial intelligence and advanced fabrication View journal scope | Submit an article |
3 July 2025
Interview with Dr. Gabriela Lima de Melo Ghisi—Winner of the Journal of Clinical Medicine 2024 Young Investigator Award
2 July 2025
MDPI INSIGHTS: The CEO's Letter #24 - 2024 Impact Factor & CiteScore, MDPI Summits France & USA, Tu Youyou Award
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI’s 2024 Impact Factor Highlights
For those of our readers who are new to academic publishing, you may have heard some news in June around the Impact Factor release. Every year, typically in June, Clarivate releases its annual Journal Citation Reports (JCR), which include Journal Impact Factors (JIF). This metric is widely used in academic publishing to reflect the average number of citations received by recent articles in each journal.
While Impact Factor is just one of many indicators of journal influence, it remains a major milestone for authors, editors, and publishers. It’s used to assess journal visibility, researcher recognition, and scholarly reach. Throughout our international meetings and events, it’s clear that the Impact Factor is something many of our authors and editorial board members care about, as it can influence where they choose to submit an article and the funding they receive for their research.
“These results reflect the trust that the scholarly community places in MDPI”
MDPI’s 2024 Impact Factor Highlights
- 298 MDPI journals received a Journal Impact Factor.
- 60 journals earned their first-ever Impact Factor
- To put this in perspective: MDPI’s 60 new journal acceptances into the Web of Science was the second highest number of any publisher in 2024, behind Elsevier and ahead of Springer Nature. Our 87% acceptance rate for journals submitted to Web of Science shows the strength of our editorial process and our proven ability to develop journals aligned with Clarivate’s 24 evaluation criteria.
- Notably, Textiles, Mathematics, International Journal of Neonatal Screening, Smart Cities, Systems, and Pharmaceutics ranked in the top 10% in their respective categories, highlighting their growing influence and prestige within their academic fields. This shows that high-quality indexing goes beyond visibility; it upholds credibility and trust.
- 193 MDPI journals are now ranked in the top 50% (Q1/Q2) of their subject categories.
- What does this mean, and why is it important? Journals are ranked by quartiles within their field, based on their Impact Factor. Q1 represents the top 25% of journals in their category, Q2 the next 25%, and so on. Being in Q1 or Q2 shows that a journal is performing well relative to other journals in its category. Authors and institutions often look at quartile rankings when choosing where to publish – it’s an important indicator of visibility and recognition, within its respective category.
- 116 of our previously ranked journals increased their Impact Factor.
- 14 MDPI journals achieved an Impact Factor of 5.0 or higher, suggesting a high degree of influence and visibility.
These results reflect our staff's hard work: from our editorial and production teams to our indexing, communications, and data teams, and beyond. This also reflects the trust that the scholarly community places in MDPI, reinforcing the message that when researchers publish with MDPI, they publish with impact.
Open Access with Impact
As the leading fully open access publisher, our journals have received a total of 18.4 million citations in the Web of Science by the end of 2024, reflecting the growing reach and engagement of research published with MDPI. We are committed to making scientific research freely accessible to everyone, everywhere. With the support of more than 4.2 million contributing authors, we’re proud to support the global shift toward open access.
Further Reading
If you’d like to better understand how journals get indexed and why Impact Factors matter, please read this recent interview with Dr. Constanze Schelhorn (Head of Indexing). It gives you a behind-the-scenes look at the role our indexing team plays in supporting journal indexing and visibility.
You can also read our official news announcement shared last week: MDPI Journals in the 2024 Journal Citation Reports.
Thank you to everyone, from our authors and reviewers to our editors and internal teams, who contributed to the progress of our journal indexing in 2024. We’re continuing to build journals that are recognized and trusted across disciplines.
Impactful Research
MDPI Journals See Continued Growth in 2024 CiteScore Results
Continuing our indexing updates, I’m pleased to share that MDPI has achieved strong results in the latest CiteScore metrics, released on 5 June by Scopus. These results reflect the collective efforts of our editors, reviewers, authors, and internal teams, with their dedication to quality and visibility in scientific publishing. You can read the full announcement here.
2024 Highlights:
- 322 MDPI journals received a CiteScore (up from 274 last year).
- 283 journals (88%) are ranked in Q1 or Q2 of their subject categories.
- 237 journals (85%) saw an increase in their CiteScore compared to last year.
- 48 journals received a CiteScore for the first time.
- 39 journals are now placed in the top 10% of their subject areas.
“This growth highlights our commitment to supporting open, trusted science”
What is CiteScore and how is it measured?
CiteScore metrics are developed by Elsevier as an alternative to the Impact Factor. They measure the citation impact of journals and can be accessed freely on Scopus. The metric represents the yearly average number of citations to recent articles published in a journal. If you’re interested in learning more about citation metrics and how we use them, check out this blog post.
Why is this important?
These results show the growing recognition for, and impact of, MDPI journals across disciplines. CiteScore rankings help researchers, institutions, and funders assess where high-quality work is being published. This growth improves our journals’ positioning in the publishing landscape and highlights our commitment to supporting open, trusted science.
Inside MDPI
Highlights from the MDPI USA Summit in Boston (5–6 June)
With several Summits already behind us, I think this is a good time to reflect on the purpose of these Summits.
Why do we organize MDPI Summits?
These one-and-a-half-day, invite-only gatherings are designed to improve our relationships with Chief Editors who lead our journals and are respected voices in their fields. The Summits aim to:
- Share MDPI’s values, achievements, editorial practices, and local market collaborations.
- Collect feedback on MDPI operations and journal practices.
- Empower Chief Editors to confidently represent MDPI beyond the Summit.
While Chief Editors know their journals well, these events help them better understand MDPI. We want them to be ambassadors for our brand. The aim is for them to walk away informed, engaged, and equipped to share positively about MDPI.
|
|
|
|
About the Boston Summit
Held on 5–6 June, our first USA Summit gathered over 25 Chief Editors to learn more about MDPI’s activities and collaborations in the USA. The program included presentations, Q&A, and a panel discussion.
Agenda Highlights:
Moderated by Summer Huggard (Operations Manager [Toronto], MDPI), the program featured:
- MDPI Overview and USA Collaboration – Stefan Tochev (CEO, MDPI)
- AI in Publishing and MDPI's Actions – Feichi Lu (Junior Data Scientist, MDPI)
- MDPI Editorial Process and Research Integrity – Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI)
- Panel Discussion – Stefan, Feichi, Giulia, Claudia
- Society Partnerships – Dr. Clàudia Aunós (Society Partnerships Senior Manager, MDPI)
- Voice of the Customer and Closing Remarks – Stefan Tochev (CEO, MDPI)
|
|
|
|
|
|
|
|
MDPI & the USA: Facts and Figures
- With over 216,000 publications, the USA is MDPI’s second-largest contributor after China.
- In 2024, the USA ranked 2nd in total submissions and 2nd in total MDPI publications, with more than 28,200 publications.
- As of 2020, the cumulative number of authors from the USA until April 2025 was 352,099.
- As at April 2025, there are more than 12,035 active Editorial Board Members (EBMs) from the USA, with 55% having an H-index over 26.
- Among them, 96 serve as Editors-in-Chief (EiC) and 218 as section-Editors-in-Chief (SEiC)
- MDPI has more than 920 Institutional Open Access Program agreements worldwide, with over 130 from the USA.
A special thanks to our Toronto team, and everyone who worked behind the scenes to make this event run smoothly.
Coming Together for Science
Highlights from the MDPI France Summit in Paris (12–13 June)
We completed our first MDPI France Summit in Paris last week, and it was a special event. Attendees were engaged from beginning to end, remaining after hours to network and collaborate.
|
|
|
|
Why a France Summit?
We chose to host a France Summit in view of the recent challenges MDPI has faced with the National Centre for Scientific Research (CNRS). What we took away from the event is that our authors and editors very much appreciate and enjoy working with us, but we need to address the concerns raised by CNRS, around Article Processing Charges (APCs) and the funding of gold open access publications.
“Our authors and editors very much enjoy working with us”
Some of the claims made in the June 2023 interview with Alain Schuhl, the Deputy CEO for Science at the CNRS, are simply not factual. For example, they state that MDPI’s “average APC charges per article are now around the same as Springer Nature’s.” Here is the relevant passage, reproduced verbatim:
This is not accurate.
A recent preprint analysing APC data from Elsevier, Springer Nature, Wiley, PLOS, MDPI, and Frontiers (2019–2023) shows that MDPI’s average APCs remain significantly lower than those of Springer Nature and several other major publishers.
The MDPI Summits are part of our outreach and communication efforts to address misconceptions and clarify MDPI’s position as one of the most accessible and affordable major gold open access publishers in the world.
Summit Overview
Held on 12–13 June, the France Summit gathered over 20 Chief Editors to learn more about MDPI’s activities and collaborations in France. Many of these editors are influential in their institutions and professional societies. Several also have connections to CNRS, which makes this an important opportunity to clarify how we operate and build trust through open and transparent communication and hopefully turn our editors into informed advocates of MDPI.
Summit Feedback
The feedback has been very positive, with most attendees completing the post-event survey and all rating the experience as Excellent or Good. A few highlights:
- “The whole thing was highly professional and, above all, provided quantified details that will allow us to better answer questions surrounding MDPI.”
- “The summit was an opportunity to meet personally various people directly engaged in the organization and policies of MDPI, which made it possible to clarify some important points concerning publishing with MDPI.”
- “Very well organized! A great opportunity to see all French MDPI partners and editors.”
Program Highlights:
Moderated by Miruna Adelina Nicolcioiu (Senior Conference Producer), the program featured:
- MDPI Overview and France Collaboration – Stefan Tochev (CEO)
- MDPI Editorial Process and Peer-Review Quality – Dr. Marta Colomer (Public Affairs Specialist)
- Institutional Partnerships and Open Access Funding Models – Becky Castellon (Institutional Partnerships Manager)
- AI in Publishing and MDPI's Actions – Daniele Raimondi (Data Scientist)
- Publication Ethics: Global Trends – Diana Cristina Apodaritei (Research Integrity Specialist)
- Closing Remarks – Stefan Tochev
- Panel Discussion – Diana, Becky, Prof. Dr. Patrick Da Cost, and Stefan
|
|
|
|
|
|
|
|
MDPI & France: Facts and Figures
- With over 51,000 publications, France is MDPI's tenth-largest contributor, and fifth largest among EU countries after Italy, Spain, Germany, and Poland.
- As of 2020, the cumulative number of authors from France until April 2025 was 87,592.
- As at April 2025, there are more than 2,800 active Editorial Board Members (EBMs) from France, with 59% having an H-index over 26.
- Among them, 22 serve as Editors-in-Chief (EiC) and 61 as section-Editors-in-Chief (SEiC)
- In 2024, IJMS, JCM, and Molecules were the top three MDPI journals in terms of submissions from French-affiliated authors.
Special thanks to our colleagues from Romanian offices for organizing this successful event.
Closing Thoughts
Richard DiMarchi and Rolf Müller Share the 2024 Tu Youyou Award
As we wrap up this month’s newsletter, I’d like to take a moment to recognize the winners of the 2024 Tu Youyou Award, presented by our journal Molecules. I am pleased to share that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.
I invite you to read the editorial co-authored by the Tu Youyou Award Committee, which highlights the significance of the award and the remarkable impact of the recipients’ research.
A sincere thank-you to the 2024 Award Committee for their dedication and selection process, and congratulations once again to this year’s honourees. Your work exemplifies the kind of research MDPI is proud to support and amplify.
|
About the Tu Youyou Award For further information about the award and the winners, please visit the Tu Youyou Award website. |
Chief Executive Officer
MDPI AG
30 June 2025
Journal of Clinical Medicine | Selected Feature Papers Published in 2024
25 June 2025
Journal of Clinical Medicine | Highly Cited Papers and Hot Topic Special Issues on Asthma
The complexity of asthma as a chronic respiratory disease makes achieving a cure challenging, but medical researchers are continuously exploring new avenues for treatment. We invite you to explore the esteemed collection of highly cited articles on asthma that have been published in Journal of Clinical Medicine (JCM, ISSN: 2077-0383) over the past two years, and we hope that they can provide you with new insights. We are currently accepting submissions for Special Issues focusing on asthma, and we look forward to your contributions.
1. “A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma”
by Keiji Oishi, Kazuki Hamada, Yoriyuki Murata, Kazuki Matsuda, Syuichiro Ohata, Yoshikazu Yamaji, Maki Asami-Noyama, Nobutaka Edakuni, Tomoyuki Kakugawa, Tsunahiko Hirano et al.
J. Clin. Med. 2023, 12(8), 2900; https://doi.org/10.3390/jcm12082900
Full text available online: https://www.mdpi.com/2077-0383/12/8/2900
2. “Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis”
by Corrado Pelaia, Giulia Pelaia, Angelantonio Maglio, Caterina Tinello, Luca Gallelli, Nicola Lombardo, Rosa Terracciano and Alessandro Vatrella
J. Clin. Med. 2023, 12(10), 3371; https://doi.org/10.3390/jcm12103371
Full text available online: https://www.mdpi.com/2077-0383/12/10/3371
3. “Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study”
by Laura Diego Bagnasco Pini, Bianca Beghè, Fulvio Braido, Paolo Cameli, Marco Caminati, Cristiano Caruso, Claudia Crimi, Gabriella Guarnieri, Manuela Latorre et al.
J. Clin. Med. 2024, 13(10), 3013; https://doi.org/10.3390/jcm13103013
Full text available online: https://www.mdpi.com/2077-0383/13/10/3013
4. “Severe Asthma and Biological Therapies: Now and the Future”
by Olaia Sardon-Prado, Carolina Diaz-Garcia, Paula Corcuera-Elosegui, Javier Korta-Murua, Jose Valverde-Molina and Manuel Sanchez-Solis
J. Clin. Med. 2023, 12(18), 5846; https://doi.org/10.3390/jcm12185846
Full text available online: https://www.mdpi.com/2077-0383/12/18/5846
5. “Reliability of Total Serum IgE Levels to Define Type 2 High and Low Asthma Phenotypes
by Giuseppe Guida, Francesca Bertolini, Vitina Carriero, Stefano Levra, Andrea Elio Sprio, Martina Sciolla, Giulia Orpheu, Elisa Arrigo, Stefano Pizzimenti, Giorgio Ciprandi et al.
J. Clin. Med. 2023, 12(17), 5447; https://doi.org/10.3390/jcm12175447
Full text available online: https://www.mdpi.com/2077-0383/12/17/5447
6. “Asthma Phenotypes in the Era of Personalized Medicine”
by Victor Gonzalez-Uribe, Sergio J. Romero-Tapia and Jose A. Castro-Rodriguez
J. Clin. Med. 2023, 12(19), 6207; https://doi.org/10.3390/jcm12196207
Full text available online: https://www.mdpi.com/2077-0383/12/19/6207
7. “Managing Small Airway Disease in Patients with Severe Asthma: Transitioning from the “Silent Zone” to Achieving “Quiet Asthma””
by Giovanna Elisiana Carpagnano, Andrea Portacci, Silvano Dragonieri, Francesca Montagnolo, Ilaria Iorillo, Ernesto Lulaj, Leonardo Maselli, Enrico Buonamico and Vitaliano Nicola Quaranta
J. Clin. Med. 2024, 13(8), 2320; https://doi.org/10.3390/jcm13082320
Full text available online: https://www.mdpi.com/2077-0383/13/8/2320
8. “Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes”
by Francesco Menzella
J. Clin. Med. 2023, 12(4), 1546; https://doi.org/10.3390/jcm12041546
Full text available online: https://www.mdpi.com/2077-0383/12/4/1546
9. “Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study”
by Hisao Higo, Hirohisa Ichikawa, Yukako Arakawa, Yoshihiro Mori, Junko Itano, Akihiko Taniguchi, Satoru Senoo, Goro Kimura, Yasushi Tanimoto, Kohei Miyake et al.
J. Clin. Med. 2023, 12(16), 5174; https://doi.org/10.3390/jcm12165174
Full text available online: https://www.mdpi.com/2077-0383/12/16/5174
10. “Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting”
by Carolina Vitale, Angelantonio Maglio, Corrado Pelaia, Maria D’Amato, Luigi Ciampo, Giulia Pelaia, Antonio Molino and Alessandro Vatrella
J. Clin. Med. 2023, 12(3), 985; https://doi.org/10.3390/jcm12030985
Full text available online: https://www.mdpi.com/2077-0383/12/3/985
| Special Issues | |
| “Advances in Allergic Diseases and Asthma: Clinical Insights and Emerging Therapies” Guest Editor: Prof. Dr. Zenon Brzoza Submission deadline: 20 October 2025 |
“Respiratory Medicine in the Oldest-Old” Guest Editor: Dr. Takae Ebihara Submission deadline: 25 October 2025 |
 |
 |
|
“New Clinical Advances in Pediatric Asthma” |
“Advances in Pulmonary Disease Management and Innovation in Treatment” |
 |
 |
23 June 2025
Journal of Clinical Medicine Travel Award—Open for Applications
19 June 2025
World Blood Donor Day—“Give Blood, Give Hope: Together We Save Lives”, 14 June 2025
On 14 June, the world celebrates World Blood Donor Day, a global tribute to the millions of voluntary, unpaid blood donors who give others a second chance at life. Their generosity saves lives, strengthens communities and embodies the spirit of solidarity. It is a day to say thank you, but also to spotlight the ongoing, urgent need for safe, regular blood donations.
The theme of the 2025 World Blood Donor Day is “Give blood, give hope: together we save lives” and the objectives of the campaign are to raise public awareness about the critical need for blood and plasma donations and the impact they have on patients' lives; encourage both new and existing donors to give blood regularly, helping to ensure a stable and sufficient blood supply; highlight the positive impact of blood donors on the health and well-being of others and promote the values of solidarity, compassion, and community through blood donation; and mobilize support from governments and development partners to invest in and sustain national blood programs to achieve universal access to safe blood transfusion worldwide.
In recognition of this important day, we recommend the following related articles, Special Issues, and journals spanning multidisciplinary fields, including clinical medicine. We believe that promoting such research contributes to enhanced public awareness of blood safety and selfless dedication.
 |
 |
 |
 |
“Sickle Cell Anemia and Inflammation: A Review of Stones and Landmarks Paving the Road in the Last 25 Years”
by Jessica Dorneles, Amanda de Menezes Mayer and José Artur Bogo Chies
Hematol. Rep. 2025, 17(1), 2; https://doi.org/10.3390/hematolrep17010002
“Patterns of Blood Transfusion in Sickle Cell Disease Hospitalizations”
by Aditi Sharma, Amit Dahiya, Asif Alavi, Indryas Woldie, Aditya Sharma, Jeffrey Karson and Vijendra Singh
Hemato 2024, 5(1), 26-34; https://doi.org/10.3390/hemato5010004
“Emerging Role of [18F]FLT PET/CT in Lymphoid Malignancies: A Review of Clinical Results”
by Anna Giulia Nappi, Giulia Santo, Lorenzo Jonghi-Lavarini, Alberto Miceli, Achille Lazzarato, Flavia La Torre, Francesco Dondi and Joana Gorica
Hematol. Rep. 2024, 16(1), 32-41; https://doi.org/10.3390/hematolrep16010004
“Understanding the Intricacies of Iron Overload Associated with β-Thalassemia: A Comprehensive Review”
by Subhangi Basu, Motiur Rahaman, Tuphan Kanti Dolai, Praphulla Chandra Shukla and
Nishant Chakravorty
Thalass. Rep. 2023, 13(3), 179-194; https://doi.org/10.3390/thalassrep13030017
“Bone Marrow Transplantation in Nonmalignant Haematological Diseases: What Have We Learned about Thalassemia?”
by Luca Castagna, Stefania Tringali, Giuseppe Sapienza, Roberto Bono, Rosario Di Maggio and Aurelio Maggio
Thalass. Rep. 2023, 13(2), 122-130; https://doi.org/10.3390/thalassrep13020011
“CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia”
by Udani Gamage, Kesari Warnakulasuriya, Sonali Hansika and Gayathri N. Silva
Thalass. Rep. 2023, 13(1), 51-69; https://doi.org/10.3390/thalassrep13010006
“Cardiovascular Complications in β-Thalassemia: Getting to the Heart of It”
by Nathalie Akiki, Mohammad H. Hodroj, Rayan Bou-Fakhredin, Kamal Matli and Ali T. Taher
Thalass. Rep. 2023, 13(1), 38-50; https://doi.org/10.3390/thalassrep13010005
“Ferritin Trajectories over Repeated Whole Blood Donations: Results from the FIND+ Study”
by Sara Moazzen, Maike G. Sweegers, Mart Janssen, Boris M. Hogema, Trynke Hoekstra and Katja Van den Hurk
J. Clin. Med. 2022, 11(13), 3581; https://doi.org/10.3390/jcm11133581
“Should We Stop Collecting the Preoperative Autologous Blood before Bone Marrow Harvest?”
by Daniel Lysák, Lenka Hejretová, Marcela Hrabětová and Pavel Jindra
J. Clin. Med. 2021, 10(10), 2134; https://doi.org/10.3390/jcm10102134
|
“Anaemia in Focus: Challenges and Solutions in Haematology” |
“Modern Blood Banking and Transfusion in Clinical Practice: Second Edition” |
 |
 |
|
“Hematopathology: Rare Hematological Diseases” |
“Feature Papers in Thalassemia Reports” |
 |
 |
